Adoption of all the proposed resolutions, with the exception of the 31st and 32nd resolutions, as recommended by the Management Board
MedinCell held its ordinary annual and extraordinary general meeting of shareholders on September 8, 2022, at MedinCell’s headquarters (3 rue des Frères Lumière, 34830 Jacou, France), which was chaired by Julie Alimi, Head of Legal of MedinCell.
With a quorum of 60.34%, the shareholders have adopted all the resolutions proposed by the Management Board and, including, the approval of the annual and consolidated accounts for exercise ended March 31, 2022, the compensation policy applicable to the Chairman and members of the Management Board, the Chairman and the members of the Supervisory Board and the delegations granted to the Management Board in financial matters. As recommended by the Management Board, resolutions 31 and 32 were rejected.
The replay of the general meeting is available on: https://www.medincell.com/fr/investisseurs/#events_
Details on the vote results will be available soon on the company’s website: https://www.medincell.com/en/investors/#meeting_